Skip to main navigation

Vor Biopharma

Menu

Bar

Bar

Our Approach
Focus & Pipeline
About Us
Investors
Join Us

News Releases

Year

October 12, 2021

Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management

Read More

September 9, 2021

VOR33 Granted U.S. FDA Fast Track Designation for AML

Read More

September 2, 2021

Vor to Participate in Three Upcoming Investor Conferences

Read More

August 9, 2021

Vor Reports Second Quarter 2021 Financial Results and Provides Company Update

Read More

July 8, 2021

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)

Read More

June 17, 2021

Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs

Read More

June 11, 2021

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

Read More

June 10, 2021

Vor to Develop Multi-Targeted CAR-Ts with Abound Bio

Read More

May 25, 2021

Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences

Read More

May 6, 2021

Vor Reports First Quarter 2021 Financial Results and Provides Company Update

Read More

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 17

Shareholder Tools

Print Page

RSS

Email Alerts

Contact IR

Search

100 Cambridgepark Dr, Suite 400, Cambridge, MA 02140

P: 617-655-6580

Email

Contact Us
Privacy Policy
Terms of Use

© 2021 Vor Biopharma. All rights reserved.